1:15pm (EST)

We wanted to give a quick update on Seattle Genetics (SGEN, $20.33, HALTED) as we have just learned the FDA committee has voted 10-0 in favor of one of its two drugs with another meeting scheduled this afternoon to review the other. 

So far, so good…